Breastfeeding and Mounjaro: the clear answer

Step 1: understand what the licence actually says

Mounjaro's licensed status in the UK does not include use during breastfeeding. The Summary of Product Characteristics (the prescribing reference that governs how clinicians use this medicine) states that tirzepatide should not be used while a patient is nursing. This is not a blanket precaution applied to every drug; it is a specific direction grounded in a genuine gap in the evidence. Animal studies with tirzepatide showed transfer into milk, which is why the guidance treats human breastfeeding as a situation requiring avoidance until proper data exists. The NHS patient information for tirzepatide reflects this: it lists breastfeeding among the conditions that mean you should not take this medicine.

A misconception worth clearing up gently: some people assume the concern is mainly about the injection route or the dose, and that a lower strength might be acceptable. The restriction applies regardless of dose. If you want a fuller picture of what the guidance covers around Mounjaro and breastfeeding, including why the evidence gap shapes the advice this way, our dedicated page walks through it in detail.

If you are currently breastfeeding and considering weight management, speak to your GP or midwife before starting any prescription treatment. There are evidence-based approaches to weight and nutrition in the postpartum period that can begin safely now.

Step 2: know what happens to your weight-management plan while you pause

For people who were on Mounjaro before becoming pregnant, or who are approaching the end of their breastfeeding period and want to restart, timing matters. Tirzepatide has a half-life of around five days, meaning it takes several weeks to clear the body fully after the last dose. Prescribers generally want a reasonable washout period before pregnancy, and the same logic applies in reverse: restarting treatment before breastfeeding has ended would reintroduce the medicine during a period when it is contraindicated.

The practical question (how long after stopping breastfeeding can treatment safely resume) is one for your prescriber, not a fixed rule to look up online. The NHS England guidance on weight-management injections is useful background reading on how these medicines are managed around major life events, including reproductive considerations. Your prescriber will want to know when breastfeeding ended, your current BMI, any weight-related health conditions, and your general health before recommending when to begin or resume.

If you were mid-titration when you stopped, do not assume you restart at the dose you left. That is a clinical decision too, and how tirzepatide treatment is structured means the titration schedule matters for tolerability.

Step 3: plan the path forward with clinical support

Once breastfeeding has ended and your prescriber confirms it is appropriate to begin or resume Mounjaro, the standard eligibility picture applies: a BMI of 30 or above, or 27 or above alongside a weight-related health condition such as high blood pressure, high cholesterol or pre-diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A prescriber assesses all of this, not just the number on the scales.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber on the same day it is submitted, a named clinician reads your answers, not automated software. For anyone transitioning back into treatment after a period of pause for pregnancy or nursing, that review includes checking your current health status and confirming the right starting point. You can read more about what private Mounjaro treatment involves and costs, or understand the guidance around conception and Mounjaro if that is also relevant to your planning.

There is also the question of alcohol during treatment, a topic that comes up often in the early months back on tirzepatide. Our guidance on drinking while taking Mounjaro covers what prescribers typically advise. Side effects are another common area of questions, and people sometimes ask whether symptoms they notice could point to something more serious, including whether Mounjaro can cause a kidney infection, which our page addresses directly. And if you have wider questions before starting a consultation, the FAQs page addresses many of the practical ones. When you are ready, checking your eligibility takes minutes and begins with a free consultation.

If anything feels uncertain while you are in the planning stage, the support team is available seven days a week.